A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands

C.A. Janssen (Corresponding Author), M.A.H. Oude Voshaar, H.E. Vonkeman, M. Krol, M.A.F.J. van de Laar

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
25 Downloads (Pure)

Abstract

Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.

Original languageEnglish
Pages (from-to)2291-2296
Number of pages6
JournalClinical rheumatology
Volume37
Issue number8
DOIs
Publication statusPublished - 1 Aug 2018

Fingerprint

Hyperuricemia
Gout
Uric Acid
Netherlands
Prescriptions
Therapeutics
Withholding Treatment
Medication Adherence
Proportional Hazards Models
Databases
Guidelines
Delivery of Health Care

Keywords

  • UT-Hybrid-D
  • Gout
  • Persistence
  • Urate-lowering therapy
  • Compliance

Cite this

@article{6b6801dacebc4aa7a0577fd643bd4ef1,
title = "A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands",
abstract = "Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7{\%} of the patients had a ULT coverage of ≥ 80{\%} of the days in 1 year (PDC ≥ 0.80), and 42.7{\%} of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.",
keywords = "UT-Hybrid-D, Gout, Persistence, Urate-lowering therapy, Compliance",
author = "C.A. Janssen and {Oude Voshaar}, M.A.H. and H.E. Vonkeman and M. Krol and {van de Laar}, M.A.F.J.",
note = "Springer deal",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10067-018-4127-x",
language = "English",
volume = "37",
pages = "2291--2296",
journal = "Clinical rheumatology",
issn = "0770-3198",
publisher = "Springer",
number = "8",

}

TY - JOUR

T1 - A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands

AU - Janssen, C.A.

AU - Oude Voshaar, M.A.H.

AU - Vonkeman, H.E.

AU - Krol, M.

AU - van de Laar, M.A.F.J.

N1 - Springer deal

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.

AB - Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.

KW - UT-Hybrid-D

KW - Gout

KW - Persistence

KW - Urate-lowering therapy

KW - Compliance

UR - http://www.scopus.com/inward/record.url?scp=85049741303&partnerID=8YFLogxK

U2 - 10.1007/s10067-018-4127-x

DO - 10.1007/s10067-018-4127-x

M3 - Article

VL - 37

SP - 2291

EP - 2296

JO - Clinical rheumatology

JF - Clinical rheumatology

SN - 0770-3198

IS - 8

ER -